Previous 10 | Next 10 |
Piper Sandler paints an upbeat outlook for the synthetic biology (SynBio) space as the firm initiates coverage on Codexis (CDXS) and Twist Biosciences (TWST).Twist Bioscience and Codexis in focus as Piper Sandler sizes up synthetic biologyThe analyst Steven Mah predict the global market for s...
The following slide deck was published by Codexis, Inc. in conjunction with this event. For further details see: Codexis (CDXS) Investor Presentation - Slideshow
Codexis, Inc. (CDXS) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Stephanie Marks - Investor Relations, Argot Partners John Nicols - President and Chief Executive Officer Ross Taylor - Chief Financial Officer Conference Call Participants Kyle Boucher - Co...
The following slide deck was published by Codexis, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Codexis, Inc. 2020 Q4 - Results - Earnings Call Presentation
Strong Product Revenue Momentum in Second Half of 2020 Drives Company’s Seventh Consecutive Year of YOY Revenue Growth Full Year Product Gross Margin Exceeds 50% for the First Time in Company’s History Company Guides to 2021 Total Revenues of $82-85M, Produ...
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences. The SVB Leerink 10 th Annual Global Healthcare Conference ...
REDWOOD CITY, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market. Codexis managemen...
REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, announced today it will be expanding its operations into a new 36,000 square foot facility in San Carlos, CA under a ten year lease. This facility will provide space fo...
High-scoring, high short-interest stocks that can benefit from ongoing short covering by hedge funds as they reduce single stock risk. Institutional quality stocks with potential catalysts that support ongoing short covering, rather than flash-in-the-pan volatility. Ideas across a...
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors. Dr. Martinborough has over t...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...